$RAPP News

BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65

Truist Securities Assumes Rapport Therapeutics at Buy, Raises Price Target to $56

BTIG Reiterates Buy on Rapport Therapeutics, Maintains $53 Price Target

Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines

Rapport Therapeutics Q1 EPS $(0.42) Beats $(0.65) Estimate, Sales $20.000M Beat $8.571M Estimate

Rapport Therapeutics To Announce Results From Phase 2a Trial Of RAP-219 At American Academy Of Neurology Annual Meeting April 18-22

Rapport Therapeutics To Announce Results From Phase 2a Trial Of RAP-219 At American Academy Of Neurology Annual Meeting April 18-22

Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript

BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $53

Wells Fargo Maintains Overweight on Rapport Therapeutics, Raises Price Target to $46

Rapport Therapeutics Files Shelf Registration To Offer Common Stock, Preferred Stock, Debt Securities, Warrants, And Units In Future Offerings; No Terms Disclosed

Rapport Therapeutics Q4 EPS $(0.72) Misses $(0.69) Estimate

Rapport Therapeutics shares are trading higher after the company announced an agreement with Tenacia Biotechnology to develop and commercialize RAP-219 in China across indications, including focal onset seizures and bipolar mania.

Rapport Therapeutics, Tenacia Biotechnology Announced Strategic Collaboration To Develop, Commercialize RAP-219 In Greater China

Rapport Therapeutics to Participate in Upcoming Investor Conferences

We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn Rate

Wells Fargo Initiates Coverage On Rapport Therapeutics with Overweight Rating, Announces Price Target of $43

Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff?

Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline